AstraZeneca Calquence approved in China for chronic lymphocytic leukaemia

Cambridge: AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic...

Related Keywords

Japan ,China ,Chinese ,Dave Fredrickson ,Li Jianyong ,National Medical Products Administration ,Astrazeneca ,Jiangsu Province ,Executive Vice President ,Oncology Business Unit ,Astrazeneca News ,Calquence ,Acalabrutinib ,Lymphocytic Leukaemia ,Rituximab ,Bendamustine ,Professor Li Jianyong , ,